Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Hemolytic disease of the newborn Stories

2012-07-31 14:22:08

FORT LEE, N.J., July 31, 2012 /PRNewswire/ -- Effective today, The Kedrion Group [www.kedrion.com] completed acquisition of the RhoGAM(®) line of products [www.RhoGAM.com] from Ortho-Clinical Diagnostics, Inc. (OCD). The acquisition includes the transfer of the Rho(D) Immune Globulin (Human) RhoGAM(®) Ultra-Filtered PLUS and Rho(D) Immune Globulin (Human) MICRhoGAM(®) Ultra-Filtered PLUS products as well as Somerset Laboratories, Inc., a wholly owned subsidiary of Ortho Clinical...

2011-04-06 10:30:00

NEW YORK, April 6, 2011 /PRNewswire/ -- KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has signed an exclusive agreement with AdnaGen, a wholly-owned subsidiary of Alere, Inc., to license specific antibodies. Under the agreement, KellBenx will have exclusive worldwide rights to commercialize the antibodies, which enable the extraction of clinically relevant information from...

2011-03-05 11:26:36

Could blood group anomaly explain Tudor king's reproductive problems and tyrannical behavior?Blood group incompatibility between Henry VIII and his wives could have driven the Tudor king's reproductive woes, and a genetic condition related to his suspected blood group could also explain Henry's dramatic mid-life transformation into a physically and mentally-impaired tyrant who executed two of his wives.Research conducted by bioarchaeologist Catrina Banks Whitley while she was a graduate...

2009-10-26 13:15:00

NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications http://www.reportlinker.com/p0155768/Reportlinker-Adds-Immunotherapies-and-Vaccines-for-Nontraditional-Indications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Executive Summary The earliest immunotherapies were vaccines that stimulate the immune system's...

2009-02-09 10:26:00

RhoGAM(R) Brand Hailed as One of the Top Achievements in 50 Years of Women's Health RARITAN, N.J., Feb. 9 /PRNewswire/ -- RhoGAM(R) Brand, the original Rh immune globulin product, celebrates its 40th year in the marketplace helping Rh-negative women in the prevention of Hemolytic Disease of the Newborn (HDN). In 1968, a new mother at Holy Name Hospital in Teaneck, N.J., helped make history as the initial recipient of the world's first injectable treatment to prevent the disease -- an event...